Rudat V, Pfreundner L, Hoppe F, Dietz A
Department of Radiation Oncology, University Clinic Hamburg, Germany.
Onkologie. 2004 Aug;27(4):368-75. doi: 10.1159/000079090.
Randomized controlled studies have shown that preservation of the larynx function in patients with advanced resectable laryngeal and hypopharyngeal cancer is possible without compromising survival compared to total laryngectomy (TL). Options for preserving the larynx include function-sparing surgery, radiotherapy alone, induction chemotherapy followed by radiotherapy of responders, and concomitant radiochemotherapy. The current data suggest that induction chemotherapy followed by radiotherapy of responders is an acceptable alternative to TL for patients desiring larynx preservation. Concomitant radiochemotherapy (platinum/5-FU) leads to superior local control and larynx preservation rates compared to induction chemotherapy followed by radiation. The optimal treatment sequence for newer cytotoxic agents is, however, unclear. Such cytotoxic agents and more effective fractionation regimens as well as more advanced surgical techniques are currently evaluated. Predictive tests to successfully stratify patients for the optimal treatment option and more effective systemic therapy are needed to improve therapeutic possibilities and survival.
随机对照研究表明,与全喉切除术(TL)相比,对于晚期可切除喉癌和下咽癌患者,在不影响生存率的情况下保留喉功能是可行的。保留喉的选择包括保留功能的手术、单纯放疗、对反应者进行诱导化疗后放疗以及同步放化疗。目前的数据表明,对于希望保留喉的患者,对反应者进行诱导化疗后放疗是TL的可接受替代方案。与诱导化疗后放疗相比,同步放化疗(铂类/5-氟尿嘧啶)可带来更好的局部控制和喉保留率。然而,新型细胞毒性药物的最佳治疗顺序尚不清楚。目前正在评估此类细胞毒性药物、更有效的分割方案以及更先进的手术技术。需要进行预测性测试,以成功地将患者分层以选择最佳治疗方案,并进行更有效的全身治疗,从而改善治疗可能性和生存率。